EVNIN LUKE 4

What Happened

• Luke Evnin, a director of Werewolf Therapeutics, sold 76,928 shares (reported as a sale) on June 9, 2026. The weighted-average price was $0.37 per share for total proceeds of $28,463. The sales were executed in multiple transactions at prices ranging from $0.3553 to $0.3851.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely).
• Transaction type: Sale (Code S), effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026 (F1).
• Price: Weighted average $0.37; individual trades ranged $0.3553–$0.3851 (F3). Reporting person can provide per-trade prices on request.
• Breakdown of shares sold by related entities: 8,242 by MPM Asset Management LLC, 52,039 by MPM BioVentures 2014, L.P., 3,471 by MPM BioVentures 2014(B), L.P., 1,791 by MPM Asset Management Investors BV2014 LLC, and 11,385 by MPM Oncology Innovations Fund, L.P. (F2).
• Shares held after the transaction (across listed entities): 32,171 (AM LLC), 203,135 (BV 2014), 13,546 (BV 2014(B)), 6,989 (AM BV2014), and 44,442 (MPM OIF) — total 300,283 shares held across those entities (F5).
• Relationship/beneficial ownership note: Evnin is a member/manager/director of the listed investment entities and disclaims direct beneficial ownership except to the extent of his pecuniary interest (F4).

Context

• This was a sale under a pre-established 10b5-1 plan, which is a routine way insiders automate trades and does not, by itself, indicate the insider’s view on the company. The sale was executed by affiliated investment entities rather than as a personal open-market block by Evnin.